OBSERVATORY EVIDENCE

Global Retinopathy of Prematurity Observatory

Examine approved ROP projects and the separately attributed scholarship of publicly associated Observatory members.

Authorship and professional affiliations do not imply Observatory ownership or institutional endorsement.

Display records

Initiative intelligence

People and projects, clearly attributed

This view connects approved ongoing work, public outputs, and current Network profiles for the selected program. A contributor affiliation is not presented as an institutional partnership.

Network intelligence

Associated Network profiles

Current approved profiles explicitly connected to this program. Professional affiliation does not imply an institutional partnership.

Checking the governed Network registry…

Open the filtered Network directory →
How to read the evidence: status, attribution and limitations

Publication status

A preprint shares findings before peer review. Submission or review does not mean acceptance.

Relationship to microscopIA

We distinguish governed projects, collaborations and independent scholarship by Network members.

Context for findings

Read the design, population, comparison and limitations alongside the numbers. Consult the full source.

Scientific evidence

Governed and collaborative projects

Explore disclosed studies and their specific scientific relationship with microscopIA. Unverified outcomes are withheld.

A selection of microscopIA research, not the complete portfolio. Some governed projects are not displayed because of nondisclosure agreements or information-protection measures before publication.

More filters
Curation and scientific governance

Interpret findings alongside the study design, population and limitations. Submission or review does not mean acceptance. Preprints have not completed journal peer review.

Curation and scientific governance →
How to read the numbers

Clinical outcomes

A percentage describes a proportion in the stated group. A risk ratio compares two risks: 1 means equal risks and 2 means twice the risk in the specified comparison. Association alone does not establish causation.

Number needed to treat

The estimated number of people treated for one additional benefit over a specified period and comparator. It depends on baseline risk and uncertainty.

Methods source ↗

Health economics

A quality-adjusted life-year (QALY) combines length and quality of life. Net monetary benefit values health gains at the stated threshold, then subtracts costs. A cost-effectiveness probability describes model uncertainty, not the probability that a patient improves.

Methods source ↗

Comparisons and precision

Read group order, units, design and follow-up with each estimate. Consult the source for confidence intervals and limitations.

microscopIA GovernedmicroscopIA CollaborationIndependent Network Record4 projects
microscopIA GovernedOriginal research · Health economic evaluationPreprint available

Retinopathy of prematurity and health economics

Economic evaluation of topical ketorolac and nepafenac prophylaxis for early-stage retinopathy of prematurity: a multicenter real-world study in Colombia

Preprint available · Under review at Cost Effectiveness and Resource Allocation
Study design
Multicenter real-world economic evaluation
Geography
Colombia · 14 centers

This study evaluates the cost-effectiveness of topical ketorolac and nepafenac prophylaxis for early-stage retinopathy of prematurity using multicenter real-world clinical and economic data from Colombia.

Design, provenance, metrics and authors
Study design
Multicenter real-world economic evaluation
Geography
Colombia · 14 centers
Initiative
Global Retinopathy of Prematurity Observatory
Preprint record
Research Square · v1
Verification source
Research Square

Public source

Public reference available

Interpret findings alongside the study design, population and limitations.

Submission or review does not mean acceptance. Preprints have not completed journal peer review.

Report a record correction →
Retinopathy of prematurityHealth economicsCost-effectivenessReal-world evidenceKetorolacNepafenacNSAIDsProphylaxis+4 more
Selected study metrics
Cohort192 infants

48 ketorolac, 98 nepafenac and 46 historical surveillance comparators.

Probability cost-effective: ketorolac71.90%
Probability cost-effective: nepafenac68.16%
Capabilities involvedHealth EconomicsResearch & EpidemiologyData Science & Statistics
Authors and manuscript affiliations

microscopIA scientists

Giliana García-AcevedoNetwork profile →Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Canada
Jorge Eduardo Silva MorenoNetwork profile →Department of Research and Innovation, microscopIA, Bogotá, Colombia
Karol Valeria Guerrero BeltránNetwork profile →Department of Research and Innovation, microscopIA, Bogotá, ColombiaSchool of Medicine, Universidad de Los Andes, Bogotá, Colombia
Wilman Sánchez-HernándezNetwork profile →Department of Research and Innovation, microscopIA, Bogotá, ColombiaDepartment of Engineering and Artificial Intelligence, microscopIA, Bogotá, Colombia
Camilo Perdomo-LunaNetwork profile →Department of Radiology and Imaging Science, Emory University, Atlanta, USASchool of Health Systems Engineering and Global Health, microscopIA, Bogotá, Colombia
Jorge RacedoNetwork profile →Department of Research and Innovation, microscopIA, Bogotá, ColombiaGlobal Studies Institute, University of Geneva, Geneva, Switzerland

External collaborators

Bryan N. Forero VásquezDepartment of Research and Innovation, microscopIA, Bogotá, ColombiaDepartment of Internal Medicine, Fundación Universitaria San Martín, Bogotá, Colombia

Record reviewed

microscopIA GovernedOriginal research · Real-world clinical evidencePreprint available

Retinopathy of prematurity

Topical ketorolac and nepafenac prophylaxis in stage 1–2 retinopathy of prematurity: A multicenter retrospective cohort study in Colombia

Preprint available · Revision at BMC Pediatrics
Study design
Multicenter real-world cohort
Geography
Colombia · multicenter care network

This study evaluates real-world clinical outcomes associated with topical ketorolac and nepafenac prophylaxis for early-stage retinopathy of prematurity across a multicenter care network in Colombia.

Design, provenance, metrics and authors
Study design
Multicenter real-world cohort
Geography
Colombia · multicenter care network
Initiative
Global Retinopathy of Prematurity Observatory
Preprint record
Research Square · v1
Verification source
Research Square

Public source

Public reference available

Interpret findings alongside the study design, population and limitations.

Submission or review does not mean acceptance. Preprints have not completed journal peer review.

Report a record correction →
Retinopathy of prematurityReal-world evidenceKetorolacNepafenacTopical NSAIDsProphylaxisClinical outcomesPediatric ophthalmology+3 more
Selected study metrics
Cohort192 infants

48 ketorolac, 98 nepafenac and 46 historical surveillance comparators.

Treatment-requiring ROP20.83% ketorolac · 22.45% nepafenac · 45.65% historical comparator
Estimated number needed to treat4 for each agent

Observational estimate, not a randomized efficacy result.

Capabilities involvedResearch & EpidemiologyData Science & StatisticsScientific Publication
Selected authors and manuscript affiliations

This is a selected list. The linked publication contains the complete, authoritative author and affiliation list.

microscopIA scientists

External collaborators

Julio C. Racero MendozaUniversidad del Sinú
Laura C. Montoya BurgosUniversidad del Sinú
Stephany Abud CogolloUniversidad Simón Bolívar

Record reviewed

microscopIA GovernedOriginal research · Health economic evaluationPreprint available

Retinopathy of prematurity and health economics

Cost-effectiveness of bevacizumab versus ranibizumab for treatment-requiring retinopathy of prematurity: a multicenter real-world cohort study

Preprint available · Under review at Cost Effectiveness and Resource Allocation
Study design
Multicenter real-world cohort and economic evaluation
Geography
Colombia · 14 centers

This study compares the cost-effectiveness of bevacizumab and ranibizumab for treatment-requiring retinopathy of prematurity using multicenter real-world clinical and economic data.

Design, provenance, metrics and authors
Study design
Multicenter real-world cohort and economic evaluation
Geography
Colombia · 14 centers
Initiative
Global Retinopathy of Prematurity Observatory
Preprint record
Research Square · v1
Verification source
Research Square

Public source

Public reference available

Interpret findings alongside the study design, population and limitations.

Submission or review does not mean acceptance. Preprints have not completed journal peer review.

Report a record correction →
Retinopathy of prematurityHealth economicsCost-effectivenessAnti-VEGFBevacizumabRanibizumabReal-world evidenceMulticenter cohort+3 more
Selected study metrics
Retreatment6.38% vs 48.65%

Observed retreatment after bevacizumab and ranibizumab, respectively.

Net monetary benefitUSD 1,022.93

Incremental net value favoring bevacizumab at the study threshold.

Probability cost-effective86.55%

Share of probabilistic simulations favoring bevacizumab.

Capabilities involvedHealth EconomicsResearch & EpidemiologyData Science & Statistics
Selected authors and manuscript affiliations

This is a selected list. The linked publication contains the complete, authoritative author and affiliation list.

microscopIA scientists

External collaborators

Andrea Carolina Rincon AlvaradomicroscopIA

Record reviewed

microscopIA GovernedOriginal research · National geospatial health-systems analysisPreprint available

Retinopathy of prematurity workforce and access

Retinopathy of prematurity care in Colombia: workforce distribution, geographic accessibility, and emerging practice patterns

Preprint available · Under review at Scientific Reports
Study design
National workforce and travel-time accessibility analysis
Geography
Colombia · 1,103 municipalities

This study characterizes the distribution of the retinopathy of prematurity workforce in Colombia, evaluates geographic accessibility to care, and examines emerging practice patterns to identify gaps relevant to national service planning.

Design, provenance, metrics and authors
Study design
National workforce and travel-time accessibility analysis
Geography
Colombia · 1,103 municipalities
Initiative
Global Retinopathy of Prematurity Observatory
Preprint record
Research Square · v1
Verification source
Research Square

Public source

Public reference available

Interpret findings alongside the study design, population and limitations.

Submission or review does not mean acceptance. Preprints have not completed journal peer review.

Report a record correction →
Retinopathy of prematurityPediatric ophthalmologyWorkforceGeographic accessibilityTravel-time accessibilityGeospatial analysisHealth systemsHealth equity+2 more
Selected study metrics
Verified providers54 clinicians
Municipalities with providers51 of 1,103 municipalities
More than 120 minutes from retina care46.30% of the population
Capabilities involvedGeospatial & Access AnalysisPolicy & Decision IntelligenceResearch & Epidemiology
Selected authors and manuscript affiliations

This is a selected list. The linked publication contains the complete, authoritative author and affiliation list.

microscopIA scientists

External collaborators

Laura Sofía Cañón BuitragoUniversidad de La Sabana
Sarah C. PérezUniversidad de Los Andes
Stephany Abud CogolloUniversidad Simón Bolívar

Record reviewed

Network intelligence

Scholarship by Observatory members

Associated members’ work is attributed to its authors and organizations. Records shown above as projects do not repeat here.

Checking member profiles and scholarship

Counts are not shown until the required records are available. This is not a zero-output result.

Browse the research catalogue →

Need a similar analysis?

Discuss your question, available data and scientific decision. Scope and feasibility are assessed for each project; previous study findings do not guarantee outcomes for a new engagement.

Discuss a Research Project →

Turn work into evidence

Bring the next clinical question or research-ready dataset.

Strong collaboration begins with a worthwhile question, governed data, and a clear decision audience.